Insulet (STU:GOV) Cyclically Adjusted Revenue per Share: €19.67 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:GOV Insulet Corp STU:GOV
77 GF Score
Price €120.60
GF Value €341.05
Valuation Significantly Undervalued
View Full Analysis

What is Insulet Cyclically Adjusted Revenue per Share?

Insulet STU:GOV +1.30% 77 Cyclically Adjusted Revenue per Share is €19.67 as of Jun. 2026. GuruFocus rates STU:GOV with a GF Score™ of 77/100 and a GF Value™ of €341.05 (Significantly Undervalued).

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Insulet's adjusted revenue per share for the three months ended in Jun. 2026 was €9.935. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €19.67 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Insulet's average Cyclically Adjusted Revenue Growth Rate was 24.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 20.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 20.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 18.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Insulet was 21.00% per year. The lowest was 3.70% per year. And the median was 19.80% per year.

As of today (2026-09-16), Insulet's current stock price is €120.60. Insulet's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €19.67. Insulet's Cyclically Adjusted PS Ratio of today is 6.13.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Insulet was 39.07. The lowest was 6.05. And the median was 18.30.


Insulet  (STU:GOV) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Insulet's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=120.60/19.666
=6.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Insulet was 39.07. The lowest was 6.05. And the median was 18.30.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Insulet Cyclically Adjusted Revenue per Share Related Terms


Insulet Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Insulet's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insulet Cyclically Adjusted Revenue per Share Chart

Insulet Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.92 9.76 11.77 14.18 17.32

Insulet Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.06 16.87 17.57 18.65 19.67

STU:GOV vs BIO, GKOS, GMED: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Insulet's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insulet Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Insulet's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Insulet's Cyclically Adjusted PS Ratio falls into.


STU:GOV
77GF Score
Insulet Corp STU:GOV
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insulet Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Insulet's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=9.935/333.9520*333.9520
=9.935

Current CPI (Jun. 2026) = 333.9520.

Insulet Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.482 241.428 2.050
201612 1.672 241.432 2.313
201703 1.654 243.801 2.266
201706 1.720 244.955 2.345
201709 1.786 246.819 2.417
201712 1.904 246.524 2.579
201803 1.719 249.554 2.300
201806 1.773 251.989 2.350
201809 2.124 252.439 2.810
201812 2.366 251.233 3.145
201903 2.298 254.202 3.019
201906 2.564 256.143 3.343
201909 2.772 256.759 3.605
201912 2.960 256.974 3.847
202003 2.858 258.115 3.698
202006 3.134 257.797 4.060
202009 2.998 260.280 3.847
202012 3.130 260.474 4.013
202103 3.168 264.877 3.994
202106 3.276 271.696 4.027
202109 3.358 274.310 4.088
202112 3.856 278.802 4.619
202203 3.769 287.504 4.378
202206 4.051 296.311 4.566
202209 4.874 296.808 5.484
202212 5.179 296.797 5.827
202303 4.761 301.836 5.268
202306 5.194 305.109 5.685
202309 5.402 307.789 5.861
202312 6.787 306.746 7.389
202403 5.519 312.332 5.901
202406 6.148 314.175 6.535
202409 6.695 315.301 7.091
202412 7.561 315.605 8.001
202503 7.295 319.799 7.618
202506 8.106 322.561 8.392
202509 8.553 324.800 8.794
202512 9.529 324.054 9.820
202603 9.274 330.213 9.379
202606 9.935 333.952 9.935

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €19.67 mean?
Insulet (STU:GOV) has a Cyclically Adjusted Revenue per Share of €19.67 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Insulet and its competitors.
Is Insulet's Cyclically Adjusted Revenue per Share too high?
Insulet's current Cyclically Adjusted Revenue per Share is €19.67. Overall, Insulet has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Insulet's Cyclically Adjusted Revenue per Share compare to BIO and GKOS?
Insulet's Cyclically Adjusted Revenue per Share of €19.67 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Insulet and its competitors. Insulet's current Cyclically Adjusted Revenue per Share is €19.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insulet stock overvalued right now?
Based on GuruFocus' analysis, Insulet (STU:GOV) is currently considered Significantly Undervalued. The stock's GF Value™ is €341.05, compared to a current price of €120.60 — trading 64.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €19.67. Insulet's overall GF Score™ is 77/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Insulet (STU:GOV), the current Cyclically Adjusted Revenue per Share is €19.67 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insulet (STU:GOV) Overvalued in 2026?

Based on GuruFocus' analysis, Insulet stock appears to be undervalued. The current stock price of €120.60 is trading 64.6% below its estimated GF Value™ of €341.05. GuruFocus considers Insulet to be Significantly Undervalued.

Key valuation signals for STU:GOV:

  • Cyclically Adjusted Revenue per Share: €19.67
  • GF Value™: €341.05 vs. price of €120.60 (64.6% below fair value)
  • GF Score™: 77/100

No single metric tells the full story. See the STU:GOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Insulet Business Description

Address 100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
77GF Score

Get the complete analysis for STU:GOV

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€120.60
Price
€341.05
GF Value